This document is the official package insert for Dupixent (Dupilumab) Injection, detailing its use for moderate-to-severe atopic dermatitis in patients aged…
This document serves as the official instruction and information leaflet for Dupixent (Dupilumab) Injection, a monoclonal antibody used to treat moderate-to-severe atopic dermatitis. It provides comprehensive guidance on the drug's composition, indications, and specific usage protocols for both adults and adolescents aged 12 to 17 years.
The text outlines detailed dosing regimens based on patient weight and age, specifying initial doses of 600mg for adults and 400mg or 600mg for adolescents, followed by maintenance doses every two weeks. It also covers administration methods, such as subcutaneous injection into the thigh or abdomen, and provides critical safety information regarding adverse reactions, contraindications, and precautions for special populations like pregnant women and those with renal impairment. This manual is written in Chinese.
| Active Ingredient | Dupilumab |
|---|---|
| Dosage Form | Pre-filled syringe |
| Strength (Adult) | 300 mg (2.0 mL)/ 支 |
| Strength (Adolescent) | 200mg (1.14 mL)/ 支 |
The recommended initial dose for adults is 600mg, administered as two 300mg injections.
Subsequent doses should be given once every two weeks at 300mg.
The initial dose is 400mg, administered as two 200mg injections.
The injection should be given subcutaneously into the thigh or abdomen, excluding the area within 5cm of the navel.